NCT07300683

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

Fratricide-Resistant Autologous Chimeric Antigen Receptor T Cells Targeting CCR9 for the Treatment of T Cell Acute Lymphoblastic Leukaemia/ Lymphoma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: University College, London · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma. Participants will: * have T cells collected from their blood and these T cells will be used to make the CAR-T cells in a specialized laboratory. * be admitted at the hospital a week before the CAR T cells infusion to receive a short course of chemotherapy drugs which prepare the body to receive the CAR T cells. * be given the CAR T cells into their vein. * stay in the hospital for a minimum of 2 weeks to be closely monitored * following discharge, participants will come to the clinic for check-ups (approximately 12 visits in the first two years) * during screening, treatment and follow up visits, participants will have physical examination, collection of blood samples and bone marrow biopsies and/or imaging tests (CT/PET-CT scans) depending on their type of T-cell cancer.

Conditions

• T Cell Acute Lymphoblastic Leukemia
• T Cell Lymphoblastic Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	CARCCR9 T cells	Anti-CCR9 CAR T cells

Timeline

• Start date: 2025-11-11
• Primary completion: 2027-12-01
• Completion: 2042-12-01
• First posted: 2025-12-24
• Last updated: 2025-12-24

Locations

1 site across 1 country: United Kingdom